Ligand Reports Fourth Quarter and Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
Ligand Pharma (LGND) Misses Q4 EPS by 45c
February 23, 2017 4:34 PM ESTLigand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.74, $0.45 worse than the analyst estimate of $1.19. Revenue for the quarter came in at $38.2 million versus the consensus estimate of $40.34 million.
GUIDANCE:
Ligand Pharma sees FY2017 EPS of $2.70.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
... More